Nebivolol is a beta-adrenergic receptor blocking agent. In extensive
metabolizers (most of the population) and at doses less than or equal to 10 mg,
nebivolol is preferentially beta1 selective. In poor metabolizers and at higher
doses, nebivolol inhibits both beta1 - and beta2 - adrenergic receptors.
Nebivolol lacks intrinsic sympathomimetic and membrane stabilizing activity at
therapeutically relevant concentrations. At clinically relevant doses, BYSTOLIC
does not demonstrate alpha1-adrenergic receptor blockade activity. Various
metabolites, including glucuronides, contribute to beta-blocking activity.
INDICATIONS AND USAGE
Hypertension: BYSTOLIC is indicated for the treatment of hypertension. BYSTOLIC
may be used alone or in combination with other antihypertensive agents.
DOSAGE AND ADMINISTRATION Hypertension:
The dose of BYSTOLIC must be individualized to the needs of the patient. For
most patients, the recommended starting dose is 5 mg once daily, with or without
food, as monotherapy or in combination with other agents. For patients requiring
further reduction in blood pressure, the dose can be increased at 2-week
intervals up to 40 mg. A more frequent dosing regimen is unlikely to be
In patients with severe renal impairment (ClCr less than 30 mL/min) the
recommended initial dose is 2.5 mg once daily; titrate up slowly if
BYSTOLIC has not been studied in patients receiving dialysis.
National Institutes of Health, U.S. National Library of Medicine,
DailyMed Database. Provides access to the latest drug monographs submitted to the
Food and Drug Administration (FDA). Please review the latest applicable package insert for
additional information and possible updates. A local search
option of this data can be found here.
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical
judgment. Neither GlobalRPh Inc. nor any other party involved in the
preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material.PLEASE READ THE DISCLAIMER
BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU
AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read